首页  期刊介绍 征稿简则 编委会 期刊征订 广告服务 留言板 联系我们 English

中国应用生理学杂志 ›› 2017, Vol. 33 ›› Issue (5): 415-419.doi: 10.12047/j.cjap.5526.2017.100

• 研究论文 • 上一篇    下一篇

右美托咪啶对肺缺血/再灌注损伤大鼠促炎介质IL-1β、TNF-α水平的影响及其机制

项冰倩1, 何金波2, 高慧1, 罗梓垠1, 戴雍月1, 王万铁1   

  1. 1. 温州医科大学缺血/再灌注损伤研究所, 浙江温州 325035;
    2. 十堰市太和医院, 湖北十堰 442000
  • 收稿日期:2016-11-24 修回日期:2017-06-23 出版日期:2017-09-28 发布日期:2018-06-19
  • 通讯作者: 王万铁,Tel:0577-86689817;E-mail:wwt@wmu.edu.cn E-mail:wwt@wmu.edu.cn
  • 基金资助:
    浙江省公益技术应用研究项目(2013C33168);浙江省新苗人才计划项目(2014R413043);温州市公益性科技计划项目(20140652)

Effects of Dexmedetomidine on the levels of proinflammatory mediators IL-1βand TNF-α in pulmonary ischemia/reperfusion injury rats and the mechanisms

XIANG Bing-qian1, HE Jin-bo2, GAO Hui1, LUO Zi-yin1, DAI Yong-yue1, WANG Wan-tie1   

  1. 1. Institute of Ischemia/Reperfusion Injury, Wenzhou Medical University, Wenzhou 325035;
    2. Shiyan Taihe Hospital, Shiyan 442000, China
  • Received:2016-11-24 Revised:2017-06-23 Online:2017-09-28 Published:2018-06-19
  • Supported by:
    浙江省公益技术应用研究项目(2013C33168);浙江省新苗人才计划项目(2014R413043);温州市公益性科技计划项目(20140652)

摘要: 目的:评价右美托咪啶对大鼠肺缺血/再灌注损伤时促炎介质肿瘤坏死因子-α(TNF-α)、白介素1β(IL-1β)的影响及机制。方法:雄性健康SPF级SD大鼠50只,体重250~310 g,8~12周龄,采用随机数字表法分为5组(n=10):假手术组(sham组)、缺血/再灌注损伤组(I/R组)、右美托咪啶组(Dex组)、阿替美唑组(Atip组)、右美托咪啶+阿替美唑组(Dex+Atip组)。采用大鼠在体左侧肺门夹闭30 min再灌注2 h制备缺血/再灌注(I/R)模型,Dex组、Atip组、Dex+Atip组分别在肺门阻断前30 min腹腔注射右美托咪啶(20 μg/kg)、阿替美唑(250 μg/kg)、右美托咪啶(20 μg/kg)和阿替美唑(250 μg/kg),其余处理同I/R组。实验结束后留取左肺检测肺湿干重比(W/D)和肺水含量(TLW);光、电镜观察肺组织形态结构变化;ELISA检测血浆中IL-1β及TNF-α的水平。结果:与sham组相比,其余各组W/D、TLW、IL-1β和TNF-α的水平明显升高(P<0.05,P<0.01),光、电镜均显示肺组织结构出现明显损伤性变化;与I/R组、Atip组、Dex+Atip组相比,Dex组W/D、TLW、IL-1β及TNF-α的含量下降(P<0.05,P<0.01),光、电镜下肺组织损伤减轻;I/R组、Atip组、Dex+Atip组两两比较,以上各指标均无统计学差异。结论:右美托咪啶通过降低促炎介质IL-1β、TNF-α浓度减轻大鼠肺缺血/再灌注损伤,其机制可能与激动α2-肾上腺素受体有关。

关键词: 右美托咪啶, 缺血/再灌注损伤, 促炎介质, IL-1β, TNF-α, 大鼠

Abstract: Objective: To evaluate the effects and mechanism of the Dexmedetomidine on the levels of proinflammatory mediators interleukin 1 beta (IL-1β) and tumor necrosis factor-α(TNF-α) in ischemia/reperfusion(I/R)rats.Methods: Fifty healthy SPF male SD rats, 250~310 g,8~12 weeks,were randomly divided into five groups(n=10):sham operation group(sham group),I/R group, dexmedetomidine group(Dex group), atipamezole group(Atip group), dexmedetomidine plus atipamezole(Dex+Atip group). The I/R model was established by clipping hilus of left lung for 30 min and then reperfusion for 2 h. Dex group, Atip group and Dex + Atip group were performed by intraperitoneal injection dexmedetomidine(20 μg/kg),atipamezole(250 μg/kg),Dexmedetomidine(20 μg/kg)+atipamezole(250 μg/kg)respectively 30 min in advance before hilus of left lung was clipped, the rest of the process was the same with I/R group. After the experiment the rats were killed and the left lung tissues to determine the lung wet/dry weight(W/D) and total lung water content(TLW); Ultra structure of lung tissues were observed under light microscope and electron microscope; IL-1β and TNF-α levels were determined by using ELISA.Results: Compared with the sham group, the W/D、TLW、IL-1β and TNF-α in other groups were increased significantly (P<0.05). The structure damages of lung tissues observed under light microscope and electron microscope in other groups were more serious than that of sham group. Compared with I/R、Atip、Dex+Atip group, the levels of W/D、TLW,IL-1β and TNF-α in Dex group were lower (P<0.05), the structure damages of lung tissues observed under light microscopy and electron microscope in Dex group were slighter. There was no significant difference of the above parameters among I/R、Atip、Dex+Atip group.Conclusion: Dexmedetomidine can alleviate ischemia/reperfusion injury in rat lung through lowering the level of proinflammatory mediators IL-1β and TNF-α,the possible mechanism may be through stimulation of α2 adrenaline receptors.

Key words: dexmedetomidine, ischemia/reperfusion injury, proinflammatory mediators, IL-1β, TNF-α, rats

版权所有 © 2015 《中国应用生理学杂志》编辑部
京ICP备16058274号-1
地址:天津市和平区大理道1号,邮编:300050  电话:022-23909086  E-mail:editor@cjap.ac.cn
本系统由北京玛格泰克科技发展有限公司设计开发 技术支持:support@magtech.com.cn